foxo4 dri peptide senolytic study The disordered p53 transactivation domain is the target of and the compound FOXO4-DRI FOXO4-DRI alleviates age-related testosterone secretion
FOXO4 DRI alleviates age related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice Aging FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data FOXO4 DRI Vial 10mg Stemcode Peptides Frontiers Senolytic Peptide FOXO4 DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
Pay in 4 interest-free payments of $5.72 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4


